Romosozumab: from basic to clinical aspects.
The Wnt pathway has an important role in bone formation. Inactivation of sclerostin, an inhibitor of this pathway, has been associated with increased bone mass both in animal experiments and in human clinical trials. Romosozumab is a humanized monoclonal antibody targeting sclerostin. Preclinical studies showed that this antibody primarily increases bone formation resulting in increased bone mineral density. Initial studies carried out in humans are in line with data obtained in animals. If these results are confirmed in larger studies with fracture end-points, this monoclonal antibody with its anabolic action, will become a key drug in the treatment of osteoporosis.
"Sapienza" Rome University, Department of Internal Medicine and Medical Disciplines , Via del Policlinico 155, 00161 Rome , Italy +39 06 49978388 ; +39 06 49978365 ; salvatore.minisola@fastwebnet.it.
Salvatore
S
Minisola
D048868:Adaptor Proteins, Signal Transducing; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D019485:Bone Morphogenetic Proteins / Q000037:antagonists & inhibitors / Q000276:immunology; D004353:Drug Evaluation, Preclinical; D005819:Genetic Markers / Q000276:immunology; D006801:Humans; D010012:Osteogenesis / Q000187:drug effects; D010024:Osteoporosis / Q000188:drug therapy*; D060449:Wnt Signaling Pathway / Q000187:drug effects
D048868:Adaptor Proteins, Signal Transducing; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D019485:Bone Morphogenetic Proteins; D005819:Genetic Markers; C422903:SOST protein, human; C557282:romosozumab
anabolic therapy; osteoporosis; romosozumab; sclerostin